Purpose
Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic
ovary syndrome.
Methods
A total of 80 women were prospectively recruited to receive either metformin (n = 40) or orlistat (n = 40). Weight, BMI, waist, serum LH, total serum testosterone and lipid profile were assessed at baseline and after 3 months.
The subjects’ ovulatory status was assessed after 3 months.
Results
There was no significant difference in ovulation between the two treatment groups (30% vs 15%). Treatment with either drug
showed a significant decline in body weight, BMI (Body Mass Index), and waist circumference, but the degree of decline in
both groups was the same. Patients who were treated with orlistat, showed a significant reduction in total testosterone and
serum lipid. Women in metformin group showed a significant reduction in serum LH.
Conclusions
Both metformin and orlistat showed a similar effect on weight loss and ovulation rates.
Keywords Metformin – Orlistat – PCOS – Weight loss – Waist circumference
Capsule
Metformin and orlistat show a similar effect on weight loss and ovulation rates in obese PCOS patients.